XML 20 R10.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements - shares					3 Months Ended
Insider Trading Arrangements - shares	Mar. 14, 2025	Mar. 10, 2025	Feb. 27, 2025	Feb. 14, 2025	Mar. 31, 2025
Trading Arrangements, by Individual
Material Terms of Trading Arrangement					During the three months ended March 31, 2025, the following officers (as defined in Rule 16a-1(f) under the Exchange Act) and directors of the Company adopted or terminated contracts, instructions or written plans for the purchase or sale of the Company’s securities that are or were intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act (each, a “Rule 10b5-1 plan”) as follows: (i) on February 14, 2025, Craig Hopkinson, M.D., our Executive Vice President, Research and Development and Chief Medical Officer, terminated a Rule 10b5-1 plan that provided for the sale of up to 820,467 ordinary shares of the Company and was scheduled to expire on July 31, 2025; (ii) on February 27, 2025, Shane Cooke, a director, adopted a Rule 10b5-1 plan providing for the sale of up to 61,200 ordinary shares of the Company that may be obtained from the exercise of vested stock options; this plan is scheduled to expire on February 27, 2026; (iii) on March 10, 2025, Christian Todd Nichols, our Senior Vice President Chief Commercial Officer, adopted a Rule 10b5-1 plan providing for the sale of up to 6,667 ordinary shares of the Company; this plan is scheduled to expire on December 9, 2025; and (iv) on March 14, 2025, Craig Hopkinson, M.D., our Executive Vice President, Research and Development and Chief Medical Officer, adopted a Rule 10b5-1 plan providing for the sale of up to 108,000 ordinary shares of the Company (including shares that may be obtained from the exercise of vested stock options); this plan is scheduled to expire on September 30, 2026. During the three months ended March 31, 2025, no other officers or directors of the Company adopted, modified or terminated a Rule 10b5-1 plan or a trading plan not intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
Rule 10b5-1 Arrangement Adopted					false
Non-Rule 10b5-1 Arrangement Adopted					false
Rule 10b5-1 Arrangement Terminated					false
Non-Rule 10b5-1 Arrangement Terminated					false
Rule 10b5-1 Arrangement Modified					false
Non-Rule 10b5-1 Arrangement Modified					false
Craig Hopkinson, M.D. [Member]
Trading Arrangements, by Individual
Name	Craig Hopkinson			Craig Hopkinson
Title	Executive Vice President, Research and Development and Chief Medical Officer			Executive Vice President, Research and Development and Chief Medical Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	March 14, 2025
Rule 10b5-1 Arrangement Terminated				true
Termination Date				February 14, 2025
Expiration Date	September 30, 2026			July 31, 2025
Aggregate Available	108,000			820,467
Shane Cooke [Member]
Trading Arrangements, by Individual
Name			Shane Cooke
Title			director
Rule 10b5-1 Arrangement Adopted			true
Adoption Date			February 27, 2025
Expiration Date			February 27, 2026
Aggregate Available			61,200
Christian Todd Nichols [Member]
Trading Arrangements, by Individual
Name		Christian Todd Nichols
Title		Senior Vice President Chief Commercial Officer
Rule 10b5-1 Arrangement Adopted		true
Adoption Date		March 10, 2025
Expiration Date		December 9, 2025
Aggregate Available		6,667